Health Catalyst, Inc. (NASDAQ:HCAT) Receives $2.84 Consensus PT from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received an average rating of “Hold” from the thirteen research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $2.8409.

Several brokerages have weighed in on HCAT. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Health Catalyst in a report on Monday, May 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Health Catalyst in a research report on Wednesday, June 24th. Wells Fargo & Company boosted their price target on Health Catalyst from $1.00 to $1.75 and gave the company an “equal weight” rating in a research note on Friday, June 26th. Finally, Stephens cut their price objective on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds and other institutional investors have recently made changes to their positions in HCAT. First Light Asset Management LLC boosted its position in shares of Health Catalyst by 17.2% during the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock worth $46,108,000 after acquiring an additional 1,793,374 shares in the last quarter. Vanguard Group Inc. raised its position in Health Catalyst by 2.9% during the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after purchasing an additional 119,117 shares in the last quarter. Whetstone Capital Advisors LLC lifted its stake in Health Catalyst by 0.5% during the fourth quarter. Whetstone Capital Advisors LLC now owns 3,750,377 shares of the company’s stock worth $8,963,000 after purchasing an additional 19,027 shares during the last quarter. Nepsis Inc. boosted its holdings in shares of Health Catalyst by 26.6% in the 4th quarter. Nepsis Inc. now owns 1,915,794 shares of the company’s stock valued at $4,579,000 after purchasing an additional 402,762 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Health Catalyst by 11.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after purchasing an additional 169,580 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $2.16 on Friday. Health Catalyst has a 12-month low of $0.96 and a 12-month high of $4.11. The company’s 50 day moving average price is $1.75 and its two-hundred day moving average price is $1.73. The firm has a market cap of $159.60 million, a PE ratio of -0.58 and a beta of 1.56. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 1.10.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Monday, May 11th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $70.76 million during the quarter, compared to the consensus estimate of $69.24 million. Health Catalyst had a negative net margin of 87.69% and a negative return on equity of 3.52%. Equities research analysts predict that Health Catalyst will post -0.25 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.